{"protocolSection": {"identificationModule": {"nctId": "NCT01634152", "orgStudyIdInfo": {"id": "205.446"}, "secondaryIdInfos": [{"id": "2011-001777-43", "type": "EUDRACT_NUMBER", "domain": "EudraCT"}], "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of 2 Doses of Tiotropium Respimat\u00ae Compared to Placebo in Children With Severe Persistent Asthma", "officialTitle": "A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (2.5 mcg and 5 mcg) Delivered Via Respimat\u00ae Inhaler Once Daily in the Evening Over 12 Weeks as add-on Controller Therapy on Top of Usual Care in Children (6 to 11 Years Old) With Severe Persistent Asthma"}, "statusModule": {"statusVerifiedDate": "2015-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-07"}, "primaryCompletionDateStruct": {"date": "2015-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-07-03", "studyFirstSubmitQcDate": "2012-07-03", "studyFirstPostDateStruct": {"date": "2012-07-06", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-11-17", "resultsFirstSubmitQcDate": "2015-11-17", "resultsFirstPostDateStruct": {"date": "2015-12-21", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-12-22", "lastUpdatePostDateStruct": {"date": "2016-01-29", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}, "collaborators": [{"name": "Pfizer", "class": "INDUSTRY"}]}, "descriptionModule": {"briefSummary": "The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution (2.5 mcg and 5 mcg) delivered via Respimat\u00ae inhaler once daily in the evening over 12 weeks, compared to placebo, as add-on controller therapy on top of usual care in children (6 to 11 years old) with severe persistent asthma."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE"}}, "enrollmentInfo": {"count": 401, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo QD", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: Placebo"]}, {"label": "Tiotropium low dose QD", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Tiotropium low dose mcg"]}, {"label": "Tiotropium medium dose QD", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Tiotropium high dose"]}], "interventions": [{"type": "DRUG", "name": "Placebo", "description": "2 actuations once daily in the evening", "armGroupLabels": ["Placebo QD"]}, {"type": "DRUG", "name": "Tiotropium low dose mcg", "description": "2 actuations once daily in the evening", "armGroupLabels": ["Tiotropium low dose QD"]}, {"type": "DRUG", "name": "Tiotropium high dose", "description": "2 actuations once daily in the evening", "armGroupLabels": ["Tiotropium medium dose QD"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "FEV1 Peak(0-3h) Change From Baseline", "description": "Change from baseline in peak forced expiratory volume in 1 second within the first 3 hours post dosing (FEV1 peak(0-3h)) measured at week 12.\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}], "secondaryOutcomes": [{"measure": "Trough FEV1 Change From Baseline", "description": "Change from baseline in Trough (pre-dose) Forced expiratory volume in 1 second (FEV1) measured at week 12.\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "FVC Peak(0-3h) Change From Baseline", "description": "Change from baseline in Maximum forced vital capacity (FVC) measured within the first 3 hours after administration of trial medication (FVC peak(0-3h)) after 12 weeks of treatment.\n\nThe measured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Trough FVC Change From Baseline", "description": "Change from baseline in Trough (pre-dose) FVC measured at week 12.\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "FEV1 AUC (0-3h) Change From Baseline", "description": "Change from baseline of area under the curve (AUC) from 0 to 3 hours for FEV1 (FEV1 AUC (0-3h)) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 12 weeks"}, {"measure": "FVC AUC (0-3h) Change From Baseline", "description": "Change from baseline of area under the curve (AUC) from 0 to 3 hours for FVC (Forced vital capacity) (FVC AUC (0-3h)) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 12 weeks"}, {"measure": "FEV1 Change From Baseline at Each Individual Timepoint", "description": "Forced expiratory volume in one second (FEV1) change from baseline at each individual timepoint.\n\nThe measured values presented are actually adjusted means.", "timeFrame": "Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 12 weeks"}, {"measure": "FVC Change From Baseline at Each Individual Timepoint", "description": "FVC change from baseline at each individual timepoint.\n\nThe measured values presented are actually adjusted means.", "timeFrame": "Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 12 weeks"}, {"measure": "Control of Asthma as Assessed by ACQ-IA Total Score", "description": "Change from baseline in Interviewer-Administered Asthma Control Questionnaire (ACQ-IA) total score measured at week 12.\n\nThe ACQ-IA is a scale containing 7 questions. Each question has a 7 point scale which ranges from 0 to 6. A score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment. ACQ-IA total score is calculated as the mean of the responses to all 7 questions.\n\nThe measured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "ACQ-IA Total Score Responders", "description": "Responder categories based on the ACQ-IA total score after 12 weeks of treatment. Analysis was performed using the following categories and definitions: responder (change from trial baseline \u2264-0.5), no change (-0.5 \\<change from trial baseline \\<0.5) and worsening (change from trial baseline \u22650.5) No statistical testing was performed for ACQ-IA total score responders.\n\nThe ACQ-IA is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment.", "timeFrame": "12 weeks"}, {"measure": "Use of PRN Rescue Medication Per Day", "description": "Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used per day (24 hour period) based on the weekly mean at week 12.\n\nThe measured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Use of PRN Rescue Medication During the Daytime", "description": "Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during the daytime based on the weekly mean at week 12.\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Use of PRN Rescue Medication During the Night-time", "description": "Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during the night-time based on the weekly mean at week 12.\n\nMeasured values presented are actually adjusted means", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Peak Expiratory Flow (PEF) a.m. Change From Baseline", "description": "Change from baseline in the morning (a.m.) peak expiratory flow based on the weekly mean at week 12.\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Peak Expiratory Flow (PEF) p.m. Change From Baseline", "description": "Change from baseline in the evening (p.m.) peak expiratory flow based on the weekly mean at week 12.\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Peak Expiratory Flow (PEF) Variability Change From Baseline", "description": "Change from baseline in the peak expiratory flow variability based on the weekly mean at week 12.\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "FEV1 a.m. Change From Baseline", "description": "Change from baseline in morning (a.m.) FEV1 based on the weekly mean at week 12.\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "FEV1 p.m. Change From Baseline", "description": "Change from baseline in evening (p.m.) FEV1 based on the weekly mean at week 12.\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Change From Baseline in Nighttime Awakenings", "description": "Change from baseline in nighttime awakenings based on the weekly mean at week 12.\n\nNighttime awakenings was assessed by the question \"Did you wake up during the night due to your asthma?\" from the e-diary. Scores range from 1 (did not wake up) to 5 (was awake all night).\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Change From Baseline in Morning Asthma Symptoms", "description": "Change from baseline in morning asthma symptoms based on the weekly mean at week 12.\n\nMorning asthma symptoms was assessed by the question \"how were your asthma symptoms this morning?\" from the e-diary. Scores range from 1 (no asthma symptoms) to 5 (very severe asthma symptoms).\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Change From Baseline in Daytime Asthma Symptoms", "description": "Change from baseline in daytime asthma symptoms based on the weekly mean at week 12.\n\nDaytime asthma symptoms was assessed by the question \"how were your asthma symptoms during the day?\" from the e-diary. Scores range from 1 (no asthma symptoms) to 5 (very severe asthma symptoms).\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Change From Baseline in Daytime Activity Limitations", "description": "Change from baseline in daytime activity limitations based on the weekly mean at week 12.\n\nDaytime activity limitations was assessed by the question \"how limited were you in your activities today because of your asthma?\" from the e-diary. Scores range from 1 (not limited) to 5 (totally limited).\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Change From Baseline in Daytime Experiences of Shortness of Breath", "description": "Change from baseline in daytime experiences of shortness of breath based on the weekly mean at week 12.\n\nDaytime experiences of shortness of breath was assessed by the question \"how much shortness of breath did you experience during the day\" from the e-diary. Scores range from 1 (none) to 5 (a very great deal).\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Change From Baseline in Daytime Experiences of Wheeze or Cough", "description": "Change from baseline in daytime experiences of wheeze or cough based on the weekly mean at week 12.\n\nDaytime experiences of wheeze or cough was assessed by the question \"did you experience wheeze or cough during the day?\" from the e-diary. Scores range from 1 (not at all) to 5 (all the time).\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Change From Baseline in Asthma Symptom-free Days", "description": "Change from baseline in asthma symptom-free days based on the weekly mean at week 12.\n\nA day was considered as an asthma symptom-free day if there were no symptoms reported via the e-Diary and no use of rescue medication reported via the eDiary during that day.\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\nInclusion criteria are:\n\n1. All patients' parent(s) (or legal guardian) must sign and date an informed consent prior to participation in the trial. In addition, an informed assent suitable for this age group has to be obtained from patients. A separate informed consent/assent is required for pharmacogenomic sampling.\n2. Male or female patients between 6 and 11 years of age.\n3. All patients must have at least a 6-month history of asthma.\n4. All patients must have been on maintenance treatment with an inhaled corticosteroid either at stable high dose in combination with another controller medication, OR at stable medium dose in combination with two other controller medications, for at least 4 weeks before Visit 1.\n5. All patients must be symptomatic (partly controlled) at Visit 1 and prior to randomisation at Visit 2 as defined by an Asthma Control Questionnaire (ACQ-IA) mean score \\>= 1.5.\n6. All patients must have a pre-bronchodilator forced expiratory volume in one second (FEV1) \\>= 60% and \\<= 90% of predicted normal at Visit 1.\n7. Variation of absolute FEV1 values of Visit 1 (pre-bronchodilator, considered as 100%) as compared to Visit 2 (pre-dose) must be within \u00b1 30%.\n8. All patients must confirm the diagnosis of asthma by bronchodilator reversibility at Visit 1, resulting in an increase in FEV1 of \\>= 12% 15 to 30 minutes after 200 mcg salbutamol/albuterol.\n9. Patients must be able to use the Respimat inhaler correctly.\n10. Patients must be able to perform all trial related procedures including technically acceptable pulmonary function tests and use of electronic diary/peak flow meter (diary compliance of at least 80% is required).\n\nExclusion criteria:\n\nExclusion criteria are:\n\n1. Patients with a significant disease other than asthma.\n2. Patients with a clinically relevant abnormal haematology or blood chemistry at screening.\n3. Patients with a history of congenital or acquired heart disease, or patients who have been hospitalised for cardiac syncope or failure during the past year.\n4. Patients with any unstable or life-threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy within the past year.\n5. Patients with a malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last five years.\n6. Patients with known active tuberculosis.\n7. Patients who have undergone thoracotomy with pulmonary resection.\n8. Patients who are currently in a pulmonary rehabilitation program or have completed a pulmonary rehabilitation program in the six weeks prior to Visit 1.\n9. Patients with known hypersensitivity to anticholinergic drugs, BAC, EDTA or any other components of the inhalation solution used with the Respimat inhaler.\n10. Pregnant or nursing female patients, including postmenarchal girls with a positive urine pregnancy test at Visit 1.\n11. Postmenarchal girls of child-bearing potential not using a highly effective method of birth control.\n12. Patients who have been treated with systemic corticosteroids within four weeks prior to Visit 1.\n13. Patients who have been treated with systemic beta-adrenergics within four weeks prior to Visit 1.\n14. Patients who have been treated with oral beta-blocker medication within four weeks prior to Visit 1 and/or during the screening period.\n15. Patients who have been treated with inhaled long-acting anticholinergics or systemic anticholinergic treatment within four weeks prior to Visit 1 and/or during the screening period, or who have been treated with inhaled short-acting anticholinergics within two weeks prior to Visit 1.\n16. Patients who have been treated with short-acting theophylline preparations within two weeks prior to Visit 1.\n17. Patients who have been treated with non-approved and according to international guidelines not recommended experimental drugs for routine asthma therapy within four weeks prior to Visit 1 and/or during the screening period.\n18. Patients who have taken an investigational drug within six half lives according to the investigator's information, or four weeks (whichever is greater) prior to Visit 1 and/or during the screening period.\n19. Patients who have previously been randomised in this trial or are currently participating in another trial.\n20. Patients with any acute asthma exacerbation or respiratory tract infection in the four weeks prior to Visit 1 and/or in the four weeks prior to Visit 2. In case of an asthma deterioration occurring in the four weeks prior to Visit 1 and/or in the four weeks prior to Visit 2, the visit must be postponed.\n21. Patients requiring six or more puffs of rescue medication per day on more than two consecutive days in the four weeks prior to Visit 1 and/or in the four weeks prior to Visit 2. In case of an asthma deterioration occurring in the four weeks prior to Visit 1 and/or in the four weeks prior to Visit 2, the visit must be postponed.\n22. Patients who are unable to comply with medication restrictions prior to Visit 1 and/or prior to Visit 2.\n23. Patients with a known narrow-angle glaucoma, or any other disease where anticholinergic treatment is contraindicated.\n24. Patients with moderate to severe renal impairment, as defined by a creatinine clearance \\<50 mL/min/1.73 m2 BSA, as tiotropium is a predominantly renally excreted drug.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "6 Years", "maximumAge": "11 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "205.446.01014 Boehringer Ingelheim Investigational Site", "city": "Rolling Hills Estates", "state": "California", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "205.446.01011 Boehringer Ingelheim Investigational Site", "city": "Denver", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "205.446.01003 Boehringer Ingelheim Investigational Site", "city": "North Dartmouth", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "205.446.01009 Boehringer Ingelheim Investigational Site", "city": "Columbia", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.95171, "lon": -92.33407}}, {"facility": "205.446.01005 Boehringer Ingelheim Investigational Site", "city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "205.446.01010 Boehringer Ingelheim Investigational Site", "city": "Oklahoma City", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "205.446.01004 Boehringer Ingelheim Investigational Site", "city": "Charleston", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "205.446.01002 Boehringer Ingelheim Investigational Site", "city": "North Charleston", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.85462, "lon": -79.97481}}, {"facility": "205.446.01012 Boehringer Ingelheim Investigational Site", "city": "Arlington", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.73569, "lon": -97.10807}}, {"facility": "205.446.01013 Boehringer Ingelheim Investigational Site", "city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "205.446.54006 Boehringer Ingelheim Investigational Site", "city": "Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "205.446.54002 Boehringer Ingelheim Investigational Site", "city": "Capital Federal", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "205.446.54003 Boehringer Ingelheim Investigational Site", "city": "Capital Federal", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "205.446.54008 Boehringer Ingelheim Investigational Site", "city": "Capital Federal", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "205.446.54005 Boehringer Ingelheim Investigational Site", "city": "Mar del Plata", "country": "Argentina", "geoPoint": {"lat": -38.00228, "lon": -57.55754}}, {"facility": "205.446.54004 Boehringer Ingelheim Investigational Site", "city": "Mendoza", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"facility": "205.446.54007 Boehringer Ingelheim Investigational Site", "city": "San Miguel de Tucuman", "country": "Argentina", "geoPoint": {"lat": -26.82414, "lon": -65.2226}}, {"facility": "205.446.61003 Boehringer Ingelheim Investigational Site", "city": "Herston", "state": "Queensland", "country": "Australia", "geoPoint": {"lat": -27.44453, "lon": 153.01852}}, {"facility": "205.446.61001 Boehringer Ingelheim Investigational Site", "city": "Perth", "state": "Western Australia", "country": "Australia", "geoPoint": {"lat": -31.95224, "lon": 115.8614}}, {"facility": "205.446.32004 Boehringer Ingelheim Investigational Site", "city": "Antwerpen", "country": "Belgium", "geoPoint": {"lat": 51.21989, "lon": 4.40346}}, {"facility": "205.446.32005 Boehringer Ingelheim Investigational Site", "city": "Brugge", "country": "Belgium", "geoPoint": {"lat": 51.20892, "lon": 3.22424}}, {"facility": "205.446.32006 Boehringer Ingelheim Investigational Site", "city": "Namur", "country": "Belgium", "geoPoint": {"lat": 50.4669, "lon": 4.86746}}, {"facility": "205.446.55001 Boehringer Ingelheim Investigational Site", "city": "Curitiba", "country": "Brazil", "geoPoint": {"lat": -25.42778, "lon": -49.27306}}, {"facility": "205.446.55007 Boehringer Ingelheim Investigational Site", "city": "Goi\u00e2nia", "country": "Brazil", "geoPoint": {"lat": -16.67861, "lon": -49.25389}}, {"facility": "205.446.55006 Boehringer Ingelheim Investigational Site", "city": "Porto Alegre", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "205.446.55002 Boehringer Ingelheim Investigational Site", "city": "Sao Paulo", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "205.446.55003 Boehringer Ingelheim Investigational Site", "city": "Sao Paulo", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "205.446.55004 Boehringer Ingelheim Investigational Site", "city": "Sao Paulo", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "205.446.55005 Boehringer Ingelheim Investigational Site", "city": "Sao Paulo", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "205.446.02003 Boehringer Ingelheim Investigational Site", "city": "London", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 42.98339, "lon": -81.23304}}, {"facility": "205.446.02001 Boehringer Ingelheim Investigational Site", "city": "Sherbrooke", "state": "Quebec", "country": "Canada", "geoPoint": {"lat": 45.40008, "lon": -71.89908}}, {"facility": "205.446.42005 Boehringer Ingelheim Investigational Site", "city": "Jablonec nad Nisou", "country": "Czech Republic", "geoPoint": {"lat": 50.72431, "lon": 15.17108}}, {"facility": "205.446.42001 Boehringer Ingelheim Investigational Site", "city": "Jihlava", "country": "Czech Republic", "geoPoint": {"lat": 49.3961, "lon": 15.59124}}, {"facility": "205.446.42002 Boehringer Ingelheim Investigational Site", "city": "Prague", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "205.446.42004 Boehringer Ingelheim Investigational Site", "city": "Prague", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "205.446.49012 Boehringer Ingelheim Investigational Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "205.446.49015 Boehringer Ingelheim Investigational Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "205.446.49001 Boehringer Ingelheim Investigational Site", "city": "Bochum", "country": "Germany", "geoPoint": {"lat": 51.48165, "lon": 7.21648}}, {"facility": "205.446.49007 Boehringer Ingelheim Investigational Site", "city": "Dresden", "country": "Germany", "geoPoint": {"lat": 51.05089, "lon": 13.73832}}, {"facility": "205.446.49003 Boehringer Ingelheim Investigational Site", "city": "Frankfurt", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "205.446.49009 Boehringer Ingelheim Investigational Site", "city": "Koblenz", "country": "Germany", "geoPoint": {"lat": 50.35357, "lon": 7.57883}}, {"facility": "205.446.49014 Boehringer Ingelheim Investigational Site", "city": "Marburg", "country": "Germany", "geoPoint": {"lat": 50.80904, "lon": 8.77069}}, {"facility": "205.446.49011 Boehringer Ingelheim Investigational Site", "city": "M\u00f6nchengladbach", "country": "Germany", "geoPoint": {"lat": 51.18539, "lon": 6.44172}}, {"facility": "205.446.50201 Boehringer Ingelheim Investigational Site", "city": "Guatemala", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "205.446.50202 Boehringer Ingelheim Investigational Site", "city": "Guatemala", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "205.446.50203 Boehringer Ingelheim Investigational Site", "city": "Guatemala", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "205.446.50204 Boehringer Ingelheim Investigational Site", "city": "Guatemala", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "205.446.36002 Boehringer Ingelheim Investigational Site", "city": "Ajka", "country": "Hungary", "geoPoint": {"lat": 47.10196, "lon": 17.55892}}, {"facility": "205.446.36001 Boehringer Ingelheim Investigational Site", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "205.446.36003 Boehringer Ingelheim Investigational Site", "city": "Nagyatad", "country": "Hungary", "geoPoint": {"lat": 46.22961, "lon": 17.35788}}, {"facility": "205.446.36004 Boehringer Ingelheim Investigational Site", "city": "Szeged", "country": "Hungary", "geoPoint": {"lat": 46.253, "lon": 20.14824}}, {"facility": "205.446.37105 Boehringer Ingelheim Investigational Site", "city": "Baldone", "country": "Latvia", "geoPoint": {"lat": 56.74278, "lon": 24.39444}}, {"facility": "205.446.37104 Boehringer Ingelheim Investigational Site", "city": "Balvi", "country": "Latvia", "geoPoint": {"lat": 57.1313, "lon": 27.26583}}, {"facility": "205.446.37108 Boehringer Ingelheim Investigational Site", "city": "Daugavpils", "country": "Latvia", "geoPoint": {"lat": 55.88333, "lon": 26.53333}}, {"facility": "205.446.37107 Boehringer Ingelheim Investigational Site", "city": "Jekabpils", "country": "Latvia", "geoPoint": {"lat": 56.49903, "lon": 25.85735}}, {"facility": "205.446.37101 Boehringer Ingelheim Investigational Site", "city": "Ogre", "country": "Latvia", "geoPoint": {"lat": 56.8162, "lon": 24.61401}}, {"facility": "205.446.37106 Boehringer Ingelheim Investigational Site", "city": "Rezekne", "country": "Latvia", "geoPoint": {"lat": 56.51025, "lon": 27.33994}}, {"facility": "205.446.37102 Boehringer Ingelheim Investigational Site", "city": "Riga", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "205.446.37103 Boehringer Ingelheim Investigational Site", "city": "Riga", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "205.446.37004 Boehringer Ingelheim Investigational Site", "city": "Siauliai", "country": "Lithuania", "geoPoint": {"lat": 55.93333, "lon": 23.31667}}, {"facility": "205.446.37003 Boehringer Ingelheim Investigational Site", "city": "Taurage", "country": "Lithuania", "geoPoint": {"lat": 55.25222, "lon": 22.28972}}, {"facility": "205.446.37002 Boehringer Ingelheim Investigational Site", "city": "Utena", "country": "Lithuania", "geoPoint": {"lat": 55.49765, "lon": 25.59918}}, {"facility": "205.446.37001 Boehringer Ingelheim Investigational Site", "city": "Vilnius", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "205.446.48004 Boehringer Ingelheim Investigational Site", "city": "Bialystok", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "205.446.48002 Boehringer Ingelheim Investigational Site", "city": "Lodz", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "205.446.48001 Boehringer Ingelheim Investigational Site", "city": "Lublin", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "205.446.48003 Boehringer Ingelheim Investigational Site", "city": "Tarnow", "country": "Poland", "geoPoint": {"lat": 50.01381, "lon": 20.98698}}, {"facility": "205.446.40002 Boehringer Ingelheim Investigational Site", "city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "205.446.70002 Boehringer Ingelheim Investigational Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "205.446.70005 Boehringer Ingelheim Investigational Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "205.446.70007 Boehringer Ingelheim Investigational Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "205.446.70011 Boehringer Ingelheim Investigational Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "205.446.70012 Boehringer Ingelheim Investigational Site", "city": "Novosibirsk", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "205.446.70001 Boehringer Ingelheim Investigational Site", "city": "St. Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "205.446.70003 Boehringer Ingelheim Investigational Site", "city": "St. Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "205.446.70004 Boehringer Ingelheim Investigational Site", "city": "St. Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "205.446.70010 Boehringer Ingelheim Investigational Site", "city": "St. Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "205.446.70009 Boehringer Ingelheim Investigational Site", "city": "Yaroslavl", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"facility": "205.446.42101 Boehringer Ingelheim Investigational Site", "city": "Kosice", "country": "Slovakia", "geoPoint": {"lat": 48.71395, "lon": 21.25808}}, {"facility": "205.446.42103 Boehringer Ingelheim Investigational Site", "city": "Presov", "country": "Slovakia", "geoPoint": {"lat": 48.99839, "lon": 21.23393}}, {"facility": "205.446.42102 Boehringer Ingelheim Investigational Site", "city": "Spisska Nova Ves", "country": "Slovakia", "geoPoint": {"lat": 48.94464, "lon": 20.56153}}, {"facility": "205.446.38013 Boehringer Ingelheim Investigational Site", "city": "Chernivtsi", "country": "Ukraine", "geoPoint": {"lat": 48.29149, "lon": 25.94034}}, {"facility": "205.446.38002 Boehringer Ingelheim Investigational Site", "city": "Dnipropetrovsk", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "205.446.38003 Boehringer Ingelheim Investigational Site", "city": "Dnipropetrovsk", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "205.446.38005 Boehringer Ingelheim Investigational Site", "city": "Donetsk", "country": "Ukraine", "geoPoint": {"lat": 48.023, "lon": 37.80224}}, {"facility": "205.446.38012 Boehringer Ingelheim Investigational Site", "city": "Donetsk", "country": "Ukraine", "geoPoint": {"lat": 48.023, "lon": 37.80224}}, {"facility": "205.446.38009 Boehringer Ingelheim Investigational Site", "city": "Kharkiv", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "205.446.38004 Boehringer Ingelheim Investigational Site", "city": "Kiev", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "205.446.38006 Boehringer Ingelheim Investigational Site", "city": "Kriviy Rig", "country": "Ukraine"}, {"facility": "205.446.38001 Boehringer Ingelheim Investigational Site", "city": "Lviv", "country": "Ukraine", "geoPoint": {"lat": 49.83826, "lon": 24.02324}}, {"facility": "205.446.38014 Boehringer Ingelheim Investigational Site", "city": "Odesa", "country": "Ukraine", "geoPoint": {"lat": 46.47747, "lon": 30.73262}}, {"facility": "205.446.38010 Boehringer Ingelheim Investigational Site", "city": "Vinnytsya", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"facility": "205.446.38011 Boehringer Ingelheim Investigational Site", "city": "Zaporizhya", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}, {"facility": "205.446.38008 Boehringer Ingelheim Investigational Site", "city": "Zaporizhzhya", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "FG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "FG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "134"}, {"groupId": "FG001", "numSubjects": "137"}, {"groupId": "FG002", "numSubjects": "130"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "130"}, {"groupId": "FG001", "numSubjects": "136"}, {"groupId": "FG002", "numSubjects": "126"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Consent withdrawn not due to AE", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Not treated", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Other reason not defined above", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Treated set which included all randomised patients who were dispensed study medication and were documented to have taken at least 1 dose of investigational treatment.", "groups": [{"id": "BG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "BG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "BG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "134"}, {"groupId": "BG001", "value": "136"}, {"groupId": "BG002", "value": "130"}, {"groupId": "BG003", "value": "400"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "9.1", "spread": "1.6"}, {"groupId": "BG001", "value": "8.8", "spread": "1.7"}, {"groupId": "BG002", "value": "9.2", "spread": "1.6"}, {"groupId": "BG003", "value": "9.0", "spread": "1.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "40"}, {"groupId": "BG003", "value": "121"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "93"}, {"groupId": "BG001", "value": "96"}, {"groupId": "BG002", "value": "90"}, {"groupId": "BG003", "value": "279"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "FEV1 Peak(0-3h) Change From Baseline", "description": "Change from baseline in peak forced expiratory volume in 1 second within the first 3 hours post dosing (FEV1 peak(0-3h)) measured at week 12.\n\nMeasured values presented are actually adjusted means.", "populationDescription": "Full Analysis Set (FAS) was the same as the treated set which included all randomised patients who were dispensed and received at least one documented dose of trial medication. Missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litres", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.252", "spread": "0.025"}, {"groupId": "OG001", "value": "0.287", "spread": "0.025"}, {"groupId": "OG002", "value": "0.391", "spread": "0.026"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Stepwise testing of the null hypothesis was used to test the efficacy of Tio R5 and then Tio R2.5, each over placebo. The analysis was performed in a stepwise manner, firstly for this endpoint, then Trough FEV1. Each step was only considered confirmatory if all previous steps were successful.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2724", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "0.035", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.028", "ciUpperLimit": "0.099", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.032", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Stepwise testing of the null hypothesis was used to test the efficacy of Tio R5 and then Tio R2.5, each over placebo. The analysis was performed in a stepwise manner, firstly for this endpoint, then Trough FEV1. Each step was only considered confirmatory if all previous steps were successful.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "0.139", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.075", "ciUpperLimit": "0.203", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.033", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "Trough FEV1 Change From Baseline", "description": "Change from baseline in Trough (pre-dose) Forced expiratory volume in 1 second (FEV1) measured at week 12.\n\nMeasured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litres", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.136", "spread": "0.027"}, {"groupId": "OG001", "value": "0.154", "spread": "0.026"}, {"groupId": "OG002", "value": "0.223", "spread": "0.027"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Stepwise testing of the null hypothesis was used to test the efficacy of Tio R5 and then Tio R2.5, each over placebo. The analysis for this endpoint was performed in a stepwise manner after the analysis of the primary endpoint was performed. Each step was only considered confirmatory if all previous steps were successful.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5898", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood", "paramType": "Mean Difference (Net)", "paramValue": "0.018", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.048", "ciUpperLimit": "0.085", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.034", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Stepwise testing of the null hypothesis was used to test the efficacy of Tio R5 and then Tio R2.5, each over placebo. The analysis for this endpoint was performed in a stepwise manner after the analysis of the primary endpoint was performed. Each step was only considered confirmatory if all previous steps were successful.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0117", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "0.087", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.019", "ciUpperLimit": "0.154", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.034", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "FVC Peak(0-3h) Change From Baseline", "description": "Change from baseline in Maximum forced vital capacity (FVC) measured within the first 3 hours after administration of trial medication (FVC peak(0-3h)) after 12 weeks of treatment.\n\nThe measured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litres", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.244", "spread": "0.028"}, {"groupId": "OG001", "value": "0.201", "spread": "0.027"}, {"groupId": "OG002", "value": "0.275", "spread": "0.028"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2277", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.043", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.113", "ciUpperLimit": "0.027", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.036", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3998", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "0.030", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.040", "ciUpperLimit": "0.101", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.036", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "Trough FVC Change From Baseline", "description": "Change from baseline in Trough (pre-dose) FVC measured at week 12.\n\nMeasured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litres", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.141", "spread": "0.029"}, {"groupId": "OG001", "value": "0.094", "spread": "0.029"}, {"groupId": "OG002", "value": "0.150", "spread": "0.030"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2030", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.048", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.121", "ciUpperLimit": "0.026", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.037", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8194", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "0.009", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.066", "ciUpperLimit": "0.083", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.038", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "FEV1 AUC (0-3h) Change From Baseline", "description": "Change from baseline of area under the curve (AUC) from 0 to 3 hours for FEV1 (FEV1 AUC (0-3h)) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).\n\nMeasured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litres", "timeFrame": "Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.175", "spread": "0.023"}, {"groupId": "OG001", "value": "0.206", "spread": "0.022"}, {"groupId": "OG002", "value": "0.301", "spread": "0.023"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2907", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "0.031", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.026", "ciUpperLimit": "0.088", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.029", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "0.126", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.068", "ciUpperLimit": "0.184", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.030", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "FVC AUC (0-3h) Change From Baseline", "description": "Change from baseline of area under the curve (AUC) from 0 to 3 hours for FVC (Forced vital capacity) (FVC AUC (0-3h)) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).\n\nMeasured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litres", "timeFrame": "Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.145", "spread": "0.025"}, {"groupId": "OG001", "value": "0.105", "spread": "0.024"}, {"groupId": "OG002", "value": "0.182", "spread": "0.025"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2008", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.041", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.103", "ciUpperLimit": "0.022", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.032", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2545", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "0.037", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.026", "ciUpperLimit": "0.100", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.032", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "FEV1 Change From Baseline at Each Individual Timepoint", "description": "Forced expiratory volume in one second (FEV1) change from baseline at each individual timepoint.\n\nThe measured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litres", "timeFrame": "Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "128"}]}], "classes": [{"title": "10 minutes pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.136", "spread": "0.027"}, {"groupId": "OG001", "value": "0.154", "spread": "0.026"}, {"groupId": "OG002", "value": "0.223", "spread": "0.027"}]}]}, {"title": "30 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.166", "spread": "0.024"}, {"groupId": "OG001", "value": "0.202", "spread": "0.023"}, {"groupId": "OG002", "value": "0.285", "spread": "0.024"}]}]}, {"title": "1 hour post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.177", "spread": "0.025"}, {"groupId": "OG001", "value": "0.203", "spread": "0.024"}, {"groupId": "OG002", "value": "0.300", "spread": "0.025"}]}]}, {"title": "2 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.191", "spread": "0.025"}, {"groupId": "OG001", "value": "0.216", "spread": "0.025"}, {"groupId": "OG002", "value": "0.324", "spread": "0.026"}]}]}, {"title": "3 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.168", "spread": "0.026"}, {"groupId": "OG001", "value": "0.215", "spread": "0.026"}, {"groupId": "OG002", "value": "0.308", "spread": "0.026"}]}]}]}, {"type": "SECONDARY", "title": "FVC Change From Baseline at Each Individual Timepoint", "description": "FVC change from baseline at each individual timepoint.\n\nThe measured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litres", "timeFrame": "Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "128"}]}], "classes": [{"title": "10 minutes pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.141", "spread": "0.029"}, {"groupId": "OG001", "value": "0.094", "spread": "0.029"}, {"groupId": "OG002", "value": "0.150", "spread": "0.030"}]}]}, {"title": "30 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.130", "spread": "0.026"}, {"groupId": "OG001", "value": "0.096", "spread": "0.026"}, {"groupId": "OG002", "value": "0.164", "spread": "0.027"}]}]}, {"title": "1 hour post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.146", "spread": "0.027"}, {"groupId": "OG001", "value": "0.097", "spread": "0.026"}, {"groupId": "OG002", "value": "0.181", "spread": "0.027"}]}]}, {"title": "2 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.159", "spread": "0.028"}, {"groupId": "OG001", "value": "0.113", "spread": "0.027"}, {"groupId": "OG002", "value": "0.199", "spread": "0.028"}]}]}, {"title": "3 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.132", "spread": "0.028"}, {"groupId": "OG001", "value": "0.110", "spread": "0.028"}, {"groupId": "OG002", "value": "0.176", "spread": "0.029"}]}]}]}, {"type": "SECONDARY", "title": "Control of Asthma as Assessed by ACQ-IA Total Score", "description": "Change from baseline in Interviewer-Administered Asthma Control Questionnaire (ACQ-IA) total score measured at week 12.\n\nThe ACQ-IA is a scale containing 7 questions. Each question has a 7 point scale which ranges from 0 to 6. A score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment. ACQ-IA total score is calculated as the mean of the responses to all 7 questions.\n\nThe measured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "126"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.026", "spread": "0.060"}, {"groupId": "OG001", "value": "1.046", "spread": "0.059"}, {"groupId": "OG002", "value": "0.948", "spread": "0.061"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7980", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "0.020", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.133", "ciUpperLimit": "0.173", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.078", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3166", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.079", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.233", "ciUpperLimit": "0.076", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.079", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "ACQ-IA Total Score Responders", "description": "Responder categories based on the ACQ-IA total score after 12 weeks of treatment. Analysis was performed using the following categories and definitions: responder (change from trial baseline \u2264-0.5), no change (-0.5 \\<change from trial baseline \\<0.5) and worsening (change from trial baseline \u22650.5) No statistical testing was performed for ACQ-IA total score responders.\n\nThe ACQ-IA is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment.", "populationDescription": "FAS, missing data for patients not withdrawn from the study were either categorised as no change or based on available data, withdrawn patients were imputed based upon discontinuation reason.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "134"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "130"}]}], "classes": [{"title": "Responder", "categories": [{"measurements": [{"groupId": "OG000", "value": "76.9"}, {"groupId": "OG001", "value": "79.4"}, {"groupId": "OG002", "value": "80.8"}]}]}, {"title": "No change", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.9"}, {"groupId": "OG001", "value": "18.4"}, {"groupId": "OG002", "value": "16.2"}]}]}, {"title": "Worsening", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.2"}, {"groupId": "OG001", "value": "2.2"}, {"groupId": "OG002", "value": "3.1"}]}]}]}, {"type": "SECONDARY", "title": "Use of PRN Rescue Medication Per Day", "description": "Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used per day (24 hour period) based on the weekly mean at week 12.\n\nThe measured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Number of puffs of rescue medication", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "127"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.570", "spread": "0.096"}, {"groupId": "OG001", "value": "-0.553", "spread": "0.094"}, {"groupId": "OG002", "value": "-0.660", "spread": "0.097"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8916", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "0.017", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.227", "ciUpperLimit": "0.261", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.124", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4789", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.089", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.336", "ciUpperLimit": "0.158", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.126", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "Use of PRN Rescue Medication During the Daytime", "description": "Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during the daytime based on the weekly mean at week 12.\n\nMeasured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Number of puffs of rescue medication", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "126"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.279", "spread": "0.057"}, {"groupId": "OG001", "value": "-0.294", "spread": "0.055"}, {"groupId": "OG002", "value": "-0.365", "spread": "0.057"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8361", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.015", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.160", "ciUpperLimit": "0.129", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.074", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2461", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.087", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.233", "ciUpperLimit": "0.060", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.075", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "Use of PRN Rescue Medication During the Night-time", "description": "Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during the night-time based on the weekly mean at week 12.\n\nMeasured values presented are actually adjusted means", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Number of puffs of rescue medication", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "126"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.285", "spread": "0.051"}, {"groupId": "OG001", "value": "-0.250", "spread": "0.050"}, {"groupId": "OG002", "value": "-0.310", "spread": "0.052"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6029", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "0.035", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.096", "ciUpperLimit": "0.165", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.067", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7034", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.026", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.158", "ciUpperLimit": "0.107", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.067", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "Peak Expiratory Flow (PEF) a.m. Change From Baseline", "description": "Change from baseline in the morning (a.m.) peak expiratory flow based on the weekly mean at week 12.\n\nMeasured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L/min", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "126"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.343", "spread": "3.613"}, {"groupId": "OG001", "value": "13.119", "spread": "3.500"}, {"groupId": "OG002", "value": "13.086", "spread": "3.630"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3083", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "4.776", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.419", "ciUpperLimit": "13.970", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.686", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3179", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "4.743", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.571", "ciUpperLimit": "14.057", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.747", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "Peak Expiratory Flow (PEF) p.m. Change From Baseline", "description": "Change from baseline in the evening (p.m.) peak expiratory flow based on the weekly mean at week 12.\n\nMeasured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L/min", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "126"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.892", "spread": "3.717"}, {"groupId": "OG001", "value": "8.459", "spread": "3.599"}, {"groupId": "OG002", "value": "3.785", "spread": "3.731"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9061", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "0.567", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.866", "ciUpperLimit": "10.001", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.807", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3990", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-4.107", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.658", "ciUpperLimit": "5.444", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.867", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "Peak Expiratory Flow (PEF) Variability Change From Baseline", "description": "Change from baseline in the peak expiratory flow variability based on the weekly mean at week 12.\n\nMeasured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of PEF", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "125"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.150", "spread": "0.777"}, {"groupId": "OG001", "value": "-0.800", "spread": "0.749"}, {"groupId": "OG002", "value": "-0.352", "spread": "0.780"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3542", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.950", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.959", "ciUpperLimit": "1.060", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.025", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6298", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.502", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.545", "ciUpperLimit": "1.541", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.042", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "FEV1 a.m. Change From Baseline", "description": "Change from baseline in morning (a.m.) FEV1 based on the weekly mean at week 12.\n\nMeasured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litres", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "126"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.174", "spread": "0.030"}, {"groupId": "OG001", "value": "0.142", "spread": "0.029"}, {"groupId": "OG002", "value": "0.125", "spread": "0.030"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4066", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.032", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.107", "ciUpperLimit": "0.043", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.038", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2032", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.049", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.125", "ciUpperLimit": "0.027", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.039", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "FEV1 p.m. Change From Baseline", "description": "Change from baseline in evening (p.m.) FEV1 based on the weekly mean at week 12.\n\nMeasured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litres", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "126"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.155", "spread": "0.031"}, {"groupId": "OG001", "value": "0.104", "spread": "0.030"}, {"groupId": "OG002", "value": "0.094", "spread": "0.032"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2064", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.051", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.131", "ciUpperLimit": "0.028", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.041", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1410", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.061", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.142", "ciUpperLimit": "0.020", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.041", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Nighttime Awakenings", "description": "Change from baseline in nighttime awakenings based on the weekly mean at week 12.\n\nNighttime awakenings was assessed by the question \"Did you wake up during the night due to your asthma?\" from the e-diary. Scores range from 1 (did not wake up) to 5 (was awake all night).\n\nMeasured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "126"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.165", "spread": "0.032"}, {"groupId": "OG001", "value": "-0.166", "spread": "0.031"}, {"groupId": "OG002", "value": "-0.159", "spread": "0.033"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9869", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.001", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.083", "ciUpperLimit": "0.082", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.042", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8730", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "0.007", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.077", "ciUpperLimit": "0.090", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.043", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Morning Asthma Symptoms", "description": "Change from baseline in morning asthma symptoms based on the weekly mean at week 12.\n\nMorning asthma symptoms was assessed by the question \"how were your asthma symptoms this morning?\" from the e-diary. Scores range from 1 (no asthma symptoms) to 5 (very severe asthma symptoms).\n\nMeasured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "126"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.207", "spread": "0.038"}, {"groupId": "OG001", "value": "-0.213", "spread": "0.037"}, {"groupId": "OG002", "value": "-0.221", "spread": "0.038"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9043", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.006", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.103", "ciUpperLimit": "0.091", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.049", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7708", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.015", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.112", "ciUpperLimit": "0.083", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.050", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Daytime Asthma Symptoms", "description": "Change from baseline in daytime asthma symptoms based on the weekly mean at week 12.\n\nDaytime asthma symptoms was assessed by the question \"how were your asthma symptoms during the day?\" from the e-diary. Scores range from 1 (no asthma symptoms) to 5 (very severe asthma symptoms).\n\nMeasured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "126"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.226", "spread": "0.040"}, {"groupId": "OG001", "value": "-0.262", "spread": "0.039"}, {"groupId": "OG002", "value": "-0.239", "spread": "0.041"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4864", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.036", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.139", "ciUpperLimit": "0.066", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.052", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7991", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.013", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.117", "ciUpperLimit": "0.090", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.053", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Daytime Activity Limitations", "description": "Change from baseline in daytime activity limitations based on the weekly mean at week 12.\n\nDaytime activity limitations was assessed by the question \"how limited were you in your activities today because of your asthma?\" from the e-diary. Scores range from 1 (not limited) to 5 (totally limited).\n\nMeasured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "126"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.210", "spread": "0.039"}, {"groupId": "OG001", "value": "-0.203", "spread": "0.038"}, {"groupId": "OG002", "value": "-0.222", "spread": "0.039"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8884", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "0.007", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.092", "ciUpperLimit": "0.106", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.050", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8115", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.012", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.112", "ciUpperLimit": "0.088", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.051", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Daytime Experiences of Shortness of Breath", "description": "Change from baseline in daytime experiences of shortness of breath based on the weekly mean at week 12.\n\nDaytime experiences of shortness of breath was assessed by the question \"how much shortness of breath did you experience during the day\" from the e-diary. Scores range from 1 (none) to 5 (a very great deal).\n\nMeasured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "126"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.204", "spread": "0.039"}, {"groupId": "OG001", "value": "-0.187", "spread": "0.038"}, {"groupId": "OG002", "value": "-0.287", "spread": "0.040"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7498", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "0.016", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.084", "ciUpperLimit": "0.117", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.051", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1108", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.083", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.185", "ciUpperLimit": "0.019", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.052", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Daytime Experiences of Wheeze or Cough", "description": "Change from baseline in daytime experiences of wheeze or cough based on the weekly mean at week 12.\n\nDaytime experiences of wheeze or cough was assessed by the question \"did you experience wheeze or cough during the day?\" from the e-diary. Scores range from 1 (not at all) to 5 (all the time).\n\nMeasured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "126"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.249", "spread": "0.045"}, {"groupId": "OG001", "value": "-0.263", "spread": "0.044"}, {"groupId": "OG002", "value": "-0.320", "spread": "0.046"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8055", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.015", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.131", "ciUpperLimit": "0.102", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.059", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2360", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.071", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.189", "ciUpperLimit": "0.047", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.060", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Symptom-free Days", "description": "Change from baseline in asthma symptom-free days based on the weekly mean at week 12.\n\nA day was considered as an asthma symptom-free day if there were no symptoms reported via the e-Diary and no use of rescue medication reported via the eDiary during that day.\n\nMeasured values presented are actually adjusted means.", "populationDescription": "FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Days", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "127"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.147", "spread": "0.031"}, {"groupId": "OG001", "value": "0.130", "spread": "0.030"}, {"groupId": "OG002", "value": "0.172", "spread": "0.031"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6748", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "-0.017", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.097", "ciUpperLimit": "0.063", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.041", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5497", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Repeated measures restricted maximum likelihood model", "paramType": "Mean Difference (Net)", "paramValue": "0.025", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.056", "ciUpperLimit": "0.105", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.041", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From first drug intake until 30 days after last drug intake, up to 164 days", "description": "The final study visit was postponed if the status of the patient could affect the primary endpoint, for example, in cases of asthma exacerbations, therefore patients could remain on treatment for longer than the planned 12 weeks.", "eventGroups": [{"id": "EG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution (2 puffs) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.", "seriousNumAffected": 2, "seriousNumAtRisk": 134, "otherNumAffected": 49, "otherNumAtRisk": 134}, {"id": "EG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.", "seriousNumAffected": 2, "seriousNumAtRisk": 136, "otherNumAffected": 36, "otherNumAtRisk": 136}, {"id": "EG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 12 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.", "seriousNumAffected": 4, "seriousNumAtRisk": 130, "otherNumAffected": 35, "otherNumAtRisk": 130}], "seriousEvents": [{"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 134}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 136}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 130}]}, {"term": "Epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 134}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 136}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 134}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 136}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 130}]}, {"term": "Asthmatic crisis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 134}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 136}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 134}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 136}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 130}]}, {"term": "Peak expiratory flow rate decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 134}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 136}, {"groupId": "EG002", "numAffected": 15, "numAtRisk": 130}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 29, "numAtRisk": 134}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 136}, {"groupId": "EG002", "numAffected": 22, "numAtRisk": 130}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights."}, "pointOfContact": {"title": "Boehringer Ingelheim Call Center", "organization": "Boehringer Ingelheim", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Bulgaria", "Norway"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069447", "term": "Tiotropium Bromide"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000010276", "term": "Parasympatholytics"}, {"id": "D000018680", "term": "Cholinergic Antagonists"}, {"id": "D000018678", "term": "Cholinergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}, {"id": "M416", "name": "Tiotropium Bromide", "asFound": "Melanoma", "relevance": "HIGH"}, {"id": "M5241", "name": "Bromides", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M13189", "name": "Parasympatholytics", "relevance": "LOW"}, {"id": "M20760", "name": "Cholinergic Antagonists", "relevance": "LOW"}, {"id": "M20758", "name": "Cholinergic Agents", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "AntiConv", "name": "Anticonvulsants"}]}}, "hasResults": true}